Cardinal Health Stock Roars Higher. Another Guidance Boost Can Do That. -- Barrons.com

Dow Jones
02/06

By Mackenzie Tatananni

Less than a month after raising its fiscal-year outlook, Cardinal Health hiked it again.

The company, which distributes pharmaceuticals and other medical supplies to customers like CVS Health, said Thursday that it now expects adjusted earnings in the range of $10.15 to $10.35 a share for the current fiscal year.

The company's previous forecast called for profit of at least $10 a share, which the company provided at the J.P. Morgan Healthcare Conference last month. The new range also is above the $10.02 a share analysts are expecting, according to FactSet.

Cardinal Health in October had guided for earnings of $9.65 to $9.85 a share, making Thursday's update the second guidance raise in the span of several months.

The stock rose 8.8% to $225.14.

CEO Jason Hollar said Thursday that Cardinal Health's "ongoing momentum" and "consistent execution against our strategic priorities" emboldened the company to boost its guidance yet again.

Cardinal Health also reported fiscal second-quarter earnings ahead of the opening bell. Adjusted earnings came to $2.63 a share, beating analysts' calls for $2.43. Revenue surged 19% to $65.6 billion in the quarter, above the $65.1 billion that Wall Street had forecast.

The company's pharmaceutical and specialty solutions business logged $60.7 billion in revenue, a 19% increase from last year. The change was driven by sales growth for existing and new clients, Cardinal Health said. Segment profit increased to $687 million from $531 million in 2024.

Revenue rose 3% to $3.3 billion within Cardinal Health's global medical products and distribution business, fueled by volume growth from existing customers, the company said.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

February 05, 2026 11:13 ET (16:13 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10